drugset / Trial / NCT02230683
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label pilot study to evaluate the safety, tolerability, and efficacy of IDN-6556 in treating portal hypertension in subjects with liver cirrhosis.
Timeline
- Start
- 2014-08
- Primary completion
- 2015-05
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emricasan | Small molecule | 25 mg | — |